

IL-35, Human, Recombinant (?????)

货号 : PCK193

产品信息

别名	Interleukin 35; IL35; hIL35
物种	Human
表达宿主	Human Cells
序列信息	asd
检索号	Q14213&P29459
分子量	73.9 kDa
标签	C-6His
生物活性	Measured by its ability to bind biotinylated human IL6RB-Fch in a functional ELISA.

产品特性

纯度	>80% as determined by reducing SDS-PAGE.
内毒素	< 1.0 EU per µg as determined by LAL test.
保存	Lyophilized protein should be stored at -5~-20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at -5~-20°C for 3 months.
运输	Ambient temperature or ice pack.
制剂	Lyophilized from a 0.2 µm filtered solution of PBS, pH7.4.



复融 Please refer to it for detailed information.

背景介绍

The novel Ebi3-IL-12 α heterodimeric Cytokine has been designated Interleukin-35 (IL-35), is a member IL12 family Cytokine produced by regulatory T cells (Treg), but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric Protein composed of IL-12 α (P35) and IL-27 β chains, which are encoded by two separate genes called IL12A and EBI3 (Epstein-Barr-virus-induced gene 3) respectively. Ectopic expression of IL-35 confers regulatory activity on naive T cells, whereas recombinant IL-35 suppresses T-cell proliferation. It identify IL-35 as a novel inhibitory Cytokine that may be specifically produced by T (reg) cells and is required for maximal suppressive activity. IL-35 has biological activity and able to expand CD4+CD25+ Treg cells, suppress the proliferation of CD4+CD25- effector cells and inhibit Th17 cell polarization. IL-35 has been shown to be constitutively expressed by regulatory T (Treg) cells CD4 (+)CD25 (+)Foxp3 (+) and suggested to contribute to their suppressive activity. IL-35 is a crucial mediator which provokes CD4+CD25+ T cell proliferation and IL-10 generation, another well-known anti-inflammatory Cytokine, along with TGFbeta Cytokine. IL-35 is a Cytokine can downregulate Th17 cell development and inhibit autoimmune inflammation. It inhibited the differentiation of Th17 cells in vitro. In vivo, IL-35 effectively attenuated established collagen-induced arthritis in mice, with concomitant suppression of IL-17 production but enhanced IFN-gamma synthesis. Thus, IL-35 is a novel anti-inflammatory Cytokine suppressing the immune response through the expansion of regulatory T cells and suppression of Th17 cell development.

